Veracyte Inc (VCYT)
NASDAQ:VCYT
Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$33.80
$0.68(1.60%)
At close: 4:00 PM EST
$33.80
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.61 - $50.71
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.11M
Market Cap
$3.98B
Enterprise Value$3.47B
Total Cash (Recent Filing)$439.06M
Total Debt (Recent Filing)$39.33M
Price to Earnings (P/E)44.0
Beta1.26
Next Earnings
Aug 11, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding79,792,650
10 Day Avg. Volume1,265,931
30 Day Avg. Volume1,112,543
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue6.41
Enterprise Value/Gross Profit8.99
Enterprise Value/Ebitda32.74
Forecast
1Y Price Target
$47.57Price Target Upside40.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.83
Revenue Forecast (FY)$586.01M
Bulls Say, Bears Say
Bulls Say
Margin And Profitability TurnaroundVeracyte shows a durable profitability inflection: expanding gross and operating margins and high adjusted EBITDA imply sustained operating leverage. This strengthens reinvestment capacity for R&D and commercialization, buffers reimbursement variability, and supports cash generation over the next 2–6 months.
Strong Cash Generation And Balance SheetSignificant cash on hand and positive operating cash flow provide financial flexibility to fund launches, commercial expansion, and selective M&A without levering the balance sheet. Low reported leverage increases resilience to reimbursement timing and execution setbacks.
Clinical Evidence Base And Product PipelineA deep evidence base (Decipher momentum, GRID databases, slide digitization) plus mid‑year product catalysts (Prosigna LDT, TruMRD) create structural diversification and higher-margin opportunities. This can sustain revenue growth and reduce reliance on any single test over time.
Bears Say
Binary Trial-readout DependenceKey commercial and guideline outcomes hinge on positive OPTIMA/ENZIMET readouts. Negative or delayed results would materially slow label expansion and guideline inclusion, undermining projected adoption and the timing of revenue contribution from these high‑impact products.
Guideline And Reimbursement Timing UncertaintyEven with positive clinical data, reimbursement and guideline updates can lag, slowing payer coverage and clinician adoption. This structural timing risk can delay monetization of new products and keeps revenue visibility contingent on external policy and payer processes.
Growth Deceleration Vs Prior Multi‑year PaceRevenue growth has slowed from prior periods to mid‑single digits TTM, suggesting market penetration or secular headwinds. Sustaining margins and ROE will require successful commercialization of new tests; absent reacceleration, returns may remain modest versus peers.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.61 and its highest was $50.71 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $3.98B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Aug 11, 2026 which is in 66 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on May 05, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.334 by $0.186.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.43.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,792,650 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.52 in its last earnings report, beating expectations of $0.334. Following the earnings report the stock price went up 24.932%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.57 (40.74% Upside)
$47.57 (40.74% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.99%
12-Months-Change
Fundamentals
Return on Equity
6.86%
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$47.57
▲(40.74% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.81% Insiders
34.98% Mutual Funds
24.09% Other Institutional Investors
1.60% Public Companies and
Individual Investors